Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Glimm

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
ESMO Open|February 6, 2026
Mismatch repair deficiency and microsatellite instability in adrenocortical carcinomaB Altieri, S Kircher, S Herterich, et al.
Leukemia|November 29, 2016
The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironmentF Fan, M H Bashari, E Morelli, et al.
The British Journal of Dermatology|June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.
ESMO Open|May 9, 2026
Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunitiesF Nichetti, P Hoffmeister, F Korell, et al.
Journal of Neuro-Oncology|January 8, 2014
NDRG1 prognosticates the natural course of disease in WHO grade II gliomaJ Blaes, M Weiler, F Sahm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinomaS M Dieter, C Heining, A Agaimy, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
Nature Medicine|June 6, 2023
The German Network for Personalized Medicine to enhance patient care and translational researchA L Illert, A Stenzinger, M Bitzer, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
ESMO Open|February 6, 2026
Mismatch repair deficiency and microsatellite instability in adrenocortical carcinomaB Altieri, S Kircher, S Herterich, et al.
Leukemia|November 29, 2016
The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironmentF Fan, M H Bashari, E Morelli, et al.
The British Journal of Dermatology|June 29, 2021
High tumour mutational burden and EGFR/MAPK pathway activation are therapeutic targets in metastatic porocarcinomaD Westphal, M Garzarolli, M Sergon, et al.
ESMO Open|May 9, 2026
Deep molecular profiling of biliary tract cancer uncovers novel biological mechanisms and therapeutic opportunitiesF Nichetti, P Hoffmeister, F Korell, et al.
Journal of Neuro-Oncology|January 8, 2014
NDRG1 prognosticates the natural course of disease in WHO grade II gliomaJ Blaes, M Weiler, F Sahm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 2016
Mutant KIT as imatinib-sensitive target in metastatic sinonasal carcinomaS M Dieter, C Heining, A Agaimy, et al.
ESMO Open|November 22, 2021
Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trialC E Heilig, P Horak, S Kreutzfeldt, et al.
ESMO Open|April 2, 2025
Comprehensive genomic and transcriptomic analysis enables molecularly guided therapy options in peritoneal and pleural mesotheliomaL Möhrmann, M Werner, M Oleś, et al.
Nature Medicine|June 6, 2023
The German Network for Personalized Medicine to enhance patient care and translational researchA L Illert, A Stenzinger, M Bitzer, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
17.6% of patients in a German cohort with exocrine pancreatic cancer were diagnosed with a genetic tumor syndrome-a case for universal genetic testing?D William, M Bermúdez, A Kübler, et al.
Pageof 4